Can You Take Fluconazole and Warfarin Together?

Fluconazole and warfarin should not be combined without close medical supervision and INR monitoring, as fluconazole can significantly increase warfarin levels and bleeding risk. While no absolute contraindication exists in FDA labeling, the combination requires dose adjustment of warfarin and frequent blood tests. Patients on this combination face a documented increased risk of over-anticoagulation and serious bleeding events.

What the FDA Says

The FDA Fluconazole label lists warfarin as an interacting drug with clinical significance. Specifically, the labeling notes that fluconazole may increase the anticoagulant effect of warfarin, potentially leading to increased prothrombin time (PT) and international normalized ratio (INR). The interaction is classified as clinically significant and requires monitoring.

Warfarin's FDA label similarly identifies azole antifungals, including fluconazole, as drugs that may potentiate anticoagulation. The label recommends monitoring PT/INR more frequently when azoles are added or discontinued. Neither drug label states an absolute contraindication, but both recommend caution and enhanced monitoring.

The FDA's FAERS (Adverse Event Reporting System) database contains numerous reports linking fluconazole use to elevated INR and bleeding complications in patients taking warfarin, though causality is not always definitively established. These cases underscore the real-world clinical significance of this interaction.

How This Interaction Works

The fluconazole-warfarin interaction occurs through hepatic cytochrome P450 enzyme inhibition. Warfarin is metabolized primarily by CYP2C9, with minor metabolism by CYP3A4 and CYP2C19. Fluconazole is a potent inhibitor of CYP2C9 and CYP3A4, meaning it slows the breakdown of warfarin in the liver.

When fluconazole inhibits CYP2C9, warfarin accumulates in the bloodstream because it is eliminated more slowly. Higher warfarin levels lead to greater anticoagulant effect—that is, more potent inhibition of vitamin K-dependent clotting factors (II, VII, IX, and X). This results in a prolonged PT/INR and increased bleeding risk.

The degree of interaction depends on several factors: fluconazole dose, duration of fluconazole therapy, warfarin dose, patient age, liver function, and genetic variations in CYP2C9 activity. Patients with the CYP2C9*2 or *3 variant alleles, which encode a less efficient enzyme, are at higher risk for warfarin accumulation and over-anticoagulation even without fluconazole. Fluconazole adds an additional layer of CYP2C9 inhibition, compounding the risk in these genetically susceptible patients.

The time course matters: fluconazole reaches steady-state plasma concentrations within 5–10 days with standard dosing (200–400 mg daily). The inhibitory effect on warfarin metabolism develops over this period, meaning INR elevation may be delayed by several days after fluconazole initiation. Conversely, when fluconazole is stopped, CYP2C9 activity gradually returns to baseline, and warfarin levels will decline, requiring upward dose adjustment to maintain therapeutic anticoagulation.

Who Is Most at Risk

Elderly patients are at particular risk. Patients over 65 years old taking warfarin have higher baseline bleeding risk due to polypharmacy, reduced renal function, and decreased hepatic metabolism. Adding fluconazole narrows the therapeutic window further.

Patients with liver disease—whether from cirrhosis, hepatitis C, or fatty liver disease—have impaired baseline warfarin metabolism. Fluconazole, which is hepatically metabolized, adds additional metabolic stress and increases accumulation risk.

Patients with reduced kidney function are at higher risk because some warfarin metabolites are renally cleared. While fluconazole undergoes mostly hepatic metabolism, both drugs can accumulate in renal impairment, raising systemic drug levels.

Patients on higher warfarin doses (above 10 mg daily) are at elevated risk because they already exist closer to the threshold for over-anticoagulation. A small relative increase in warfarin levels from fluconazole can push them into the supratherapeutic range.

Patients taking multiple CYP2C9 inhibitors face compounded risk. Drugs like amiodarone, certain NSAIDs (ibuprofen, naproxen), sulfamethoxazole, and some statins also inhibit CYP2C9. Adding fluconazole creates a multi-drug interaction that dramatically slows warfarin clearance.

Patients with genetic CYP2C9 variants (*2 and *3 alleles) have intrinsically slower warfarin metabolism. These patients require lower maintenance warfarin doses, and the addition of fluconazole creates outsized risk.

Clinical Scenario 1: Acute Fungal Infection Requiring Short-Term Fluconazole

A 68-year-old male with a mechanical heart valve has been stable on warfarin 5 mg daily for 3 years, maintaining an INR between 2.0 and 3.0. He develops an acute candida esophagitis and is prescribed fluconazole 400 mg loading dose, then 200 mg daily for 14 days. His most recent INR was 2.2 two weeks prior.

On day 5 of fluconazole therapy, he has no symptoms, but routine INR monitoring reveals an INR of 4.1 (supratherapeutic). His warfarin metabolism has been slowed by fluconazole's CYP2C9 inhibition, causing unexpected accumulation. His physician reduces his warfarin dose to 3 mg daily and repeats INR testing in 3 days.

Day 8 INR is 3.8. Warfarin is reduced further to 2 mg daily. The patient completes fluconazole on day 14. By day 18, INR is 2.9 (therapeutic). Over the next week, as fluconazole clears and CYP2C9 activity returns, his INR begins trending downward. By day 25, his INR is 1.8 (subtherapeutic). His warfarin is increased back to 4.5 mg daily to re-establish therapeutic anticoagulation.

This case illustrates the dynamic nature of the interaction: fluconazole causes rapid INR elevation, requiring downward warfarin adjustment, then causes rapid INR decline after fluconazole discontinuation, requiring upward adjustment. Without frequent monitoring, this patient could have experienced either hemorrhage (if INR stayed at 4.1) or thrombosis (if warfarin remained reduced after fluconazole stopped).

Clinical Scenario 2: Chronic Azole Therapy with Chronic Anticoagulation

A 72-year-old female with atrial fibrillation on warfarin 6 mg daily (INR goal 2–3) develops chronic pulmonary coccidioidomycosis requiring fluconazole 400 mg daily for 6 months or longer. Her baseline INR has been stable at 2.4.

One week after fluconazole starts, INR is 3.6. Warfarin is reduced to 4 mg daily. Two weeks into fluconazole, INR is 3.1 (acceptable). After stabilizing for 3 weeks on warfarin 4 mg plus fluconazole, her INR remains between 2.5 and 3.1.

At 3 months, fluconazole is successfully discontinued due to clinical improvement. Within 5 days, her INR begins declining. By day 10 post-discontinuation, INR is 1.9 (subtherapeutic). Warfarin is increased back to 5.5 mg daily. INR returns to target by day 14.

This scenario illustrates chronic co-administration: the interaction reaches a new steady state (lower warfarin dose maintains target INR), but discontinuation requires rapid warfarin dose adjustment to prevent loss of anticoagulation and thrombotic risk.

What to Do

If You Are Already on Warfarin and Prescribed Fluconazole: Inform your doctor and pharmacist immediately. Do not start fluconazole without explicit permission from the prescriber who manages your anticoagulation. Your warfarin dose will likely need to be reduced.

Expect More Frequent INR Testing: Standard warfarin monitoring (every 4–12 weeks) is inadequate during fluconazole co-administration. Ask your doctor to schedule INR testing at days 3–5 after fluconazole starts, then every 3–5 days during the first 2 weeks. After that, testing every 1–2 weeks is prudent for the duration of fluconazole therapy.

Plan for Dose Adjustments: Understand that your warfarin dose will likely be reduced while on fluconazole and increased again after fluconazole stops. Your doctor may reduce warfarin proactively by 20–30% when fluconazole is added, based on prior response patterns.

Avoid Additional CYP2C9 Inhibitors: While on fluconazole, ask your pharmacist before starting NSAIDs, additional antimicrobials, or other new drugs. The combination of fluconazole plus another CYP2C9 inhibitor dramatically increases over-anticoagulation risk.

Consider Alternative Antifungals if Appropriate: For some fungal infections, alternatives exist. Terbinafine (for dermatophytes) does not inhibit CYP2C9. Caspofungin (for Candida) has minimal drug interactions. Discuss with your infectious disease specialist whether a warfarin-sparing antifungal is suitable for your infection type and severity.

Keep a Medication List: Bring a written list of all medications (including over-the-counter drugs and supplements) to each appointment. Highlight that you are on warfarin and fluconazole together.

When to Call Your Doctor or Pharmacist

Contact your healthcare provider immediately if you experience:

• Unusual bleeding: Blood in urine or stool, nosebleeds that do not stop within 10 minutes, bleeding gums, or vaginal bleeding between periods
• Bruising: Large or unexplained bruises, or bruises that appear spontaneously without trauma
• Severe headache or dizziness: Especially if accompanied by weakness, confusion, or vision changes (may indicate intracranial hemorrhage)
• Abdominal pain or swelling: May indicate gastrointestinal bleeding
• Chest pain or shortness of breath: May indicate thromboembolism (blood clot) if INR drops too low after fluconazole discontinuation
• Missed INR appointment: If you cannot attend a scheduled INR test, contact your anticoagulation clinic or doctor to reschedule urgently

Also notify your doctor if you experience signs that fluconazole may not be working—ongoing oral thrush, persistent fever, or worsening fungal infection symptoms—as dose changes might be needed that further complicate warfarin management.

Key Takeaways

• Fluconazole inhibits the CYP2C9 enzyme that metabolizes warfarin, causing warfarin accumulation and increased bleeding risk; the combination requires warfarin dose reduction and frequent INR monitoring.
• INR elevation typically develops 3–7 days after fluconazole initiation; INR decline begins within days of fluconazole discontinuation, requiring upward warfarin adjustment to avoid loss of anticoagulation.
• Elderly patients, those with liver disease, and patients on higher warfarin doses face the greatest risk; genetic variants in CYP2C9 further increase susceptibility.
• During fluconazole co-administration, INR should be checked every 3–5 days initially, then every 1–2 weeks, with warfarin doses adjusted based on results.
• Always inform your anticoagulation provider and pharmacist before starting any azole antifungal while on warfarin, and ask about warfarin-sparing antifungal alternatives if they are appropriate for your infection.

Sources

• FDA Drug Labeling for Fluconazole (Diflucan): https://open.fda.gov — Search "Fluconazole" for current FDA-approved label
• FDA Drug Labeling for Warfarin: https://open.fda.gov — Search "Warfarin" for current FDA-approved label
• Holbrook, A. M., et al. (2012). Evidence-based management of anticoagulation for stroke prevention in atrial fibrillation. Chest, 141(2_suppl), e531S-e575S. PMID: 22315270
• Harder, S., Thurmann, P. (1996). Clinically important drug interactions with anticoagulants: an update. Clinical Pharmacokinetics, 30(6), 416-444. PMID: 8792057
• FDA FAERS (Adverse Event Reporting System): https://fis.fda.gov — Public database of adverse event reports
• National Institutes of Health, Warfarin-Drug Interactions: https://medlineplus.gov — MedlinePlus resource on warfarin interactions
• Stockley, I. H. (Ed.). (2023). Stockley's Drug Interactions. 12th ed. London: Pharmaceutical Press. — Clinical reference for drug-drug interaction mechanisms

Protect Your Health: Check All Your Drug Interactions

The fluconazole-warfarin interaction is just one example of how two common medications can interact in ways that increase your risk of serious harm. Every time you start a new drug—whether prescribed, over-the-counter, or herbal—you should check it against your entire medication list. The best way to catch potential interactions before they cause bleeding, clotting, or other adverse events is to use a comprehensive drug interaction checker. Visit checkdruginteractions.com to enter all your medications and get detailed, evidence-based interaction data powered by FDA labeling and NIH resources. Your pharmacist can review the results with you, but taking 2 minutes to check yourself could prevent a serious adverse event. Your anticoagulation care is only as safe as your full medication picture.